Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

During the Trading Day
97.80 +0.55 / +0.57%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
97.47 -0.3339 / -0.34%
Volume: 12.2K
Health Technology

Company Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Contact Information

Alnylam Pharmaceuticals, Inc.
300 Third Street
Cambridge Massachusetts 02142
P:(617) 551-8200
Investor Relations:
(617) 551-8207



Mutual fund holders51.19%
Other institutional27.48%
Individual stakeholders25.53%

Top Executives

John M. MaraganoreChief Executive Officer & Director
Barry E. GreenePresident & Chief Operating Officer
Michael P. MasonTreasurer & Vice President-Finance
Rachel MeyersVice President-Research
Akshay K. VaishnawChief Medical Officer & Executive Vice President